Literature DB >> 18369205

New treatments for kidney cancer.

Jonathan Waxman, Laura Kenny, Sarah Ngan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18369205      PMCID: PMC2276289          DOI: 10.1136/bmj.39469.564734.80

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  8 in total

1.  Renal-cell carcinoma--molecular pathways and therapies.

Authors:  James Brugarolas
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

2.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.

Authors:  John D Hainsworth; Jeffrey A Sosman; David R Spigel; Donna L Edwards; Cara Baughman; Anthony Greco
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

3.  Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact.

Authors:  G Hofmockel; S Riess; I D Bassukas; J Dämmrich
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

4.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

6.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

7.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

8.  EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization.

Authors:  H Moch; G Sauter; T C Gasser; L Bubendorf; J Richter; J C Presti; F M Waldman; M J Mihatsch
Journal:  J Pathol       Date:  1998-04       Impact factor: 7.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.